Levetiracetam
Other Antiepileptics
Sold as Matever · Epixram · KEPPRA
- Drug class
- Other Antiepileptics
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 4
- Products on record
- 378
- FDA reports (12 mo)
- 7,196
Overview
Plain-language summary, compiled from the cited regulatory records
Levetiracetam is an antiepileptic medication [1]. It belongs to the drug class of other antiepileptics [1].
Levetiracetam is approved for treating partial-onset seizures in individuals 1 month of age and older [1]. It is also used as an add-on therapy for myoclonic seizures in patients 12 years and older who have juvenile myoclonic epilepsy [1]. Additionally, it is indicated as adjunctive therapy for primary generalized tonic-clonic seizures in patients 6 years and older with idiopathic generalized epilepsy [1].
In the market, levetiracetam is available under several brand names [1]. There were 7,196 adverse event reports for levetiracetam in the last 12 months [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 295 | May 22, 2026 |
| CA Canada | Health Canada | 61 | March 19, 2026 |
| US United States | FDA | 13 | March 23, 2026 |
| EU European Union | EMA | 9 | April 1, 2026 |
GBUnited Kingdom· MHRA
295 products
Uses
Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Levetiracetam is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
How to take
CACanada· Health Canada
61 products
Uses
LEVETIRACETAM (levetiracetam) is indicated as adjunctive therapy in the management of adult (> 18 years of age) patients with epilepsy who are not satisfactorily controlled by conventional therapy. 3 Pharmacokinetics, Special Populations and Conditions, Pediatrics).
3 Pharmacokinetics, Special Populations and Conditions, Geriatrics).
How to take
USUnited States· FDA
13 products
Uses
1 Partial Onset Seizures Levetiracetam tablets USP are indicated for treatment of partial-onset seizures in patients 1 month of age and older. 2 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy Levetiracetam tablets USP are indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy.
3 Primary Generalized Tonic-Clonic Seizures Levetiracetam tablets USP are indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy.
How to take
EUEuropean Union· EMA
9 products
Uses
Keppra is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Keppra is indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy.
• in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.
How to take
Drug interactions
Known interactions involving Levetiracetam. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 435. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL203950344 · revised May 22, 2026
- [2]Health Canada (DPD) · 02407159 · revised March 19, 2026
- [3]FDA DailyMed · 02e237ff-a3e0-40… · revised March 23, 2026 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000277 · revised April 1, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.